Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1/2 dose-escalation study

Blood

Volumn 116, Issue 23, 2010, Pages 4777-4782

  Moreau, Philippe ^a   Jaccard, Arnaud ^b   Benboubker, Lotfi ^c   Royer, Bruno ^d   Leleu, Xavier ^e   Bridoux, Franck ^f   Salles, Gilles ^g   Leblond, Veronique ^h   Roussel, Murielle ⁱ   Alakl, May ^j   Hermine, Olivier ^k   Planche, Lucie ^a   Harousseau, Jean Luc ^l   Fermand, Jean Paul ^m  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g University Hospital   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j Celgene   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l CENTRE RENÉ GAUDUCHEAU   (France)

^m SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; MELPHALAN;

ABDOMINAL DISTENSION; ADULT; AGED; AMYLOIDOSIS; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BRAIN ISCHEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; EVENT FREE SURVIVAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERPIGMENTATION; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RASH; SINGLE DRUG DOSE; SKIN ATROPHY; SYSTOLIC DYSFUNCTION; THROMBOSIS; TREATMENT RESPONSE; URINE RETENTION; XEROSTOMIA;

EID: 78649759752     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-294405     Document Type: Article

References (23)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596.
2. Comenzo RL. How I treat amyloidosis. Blood. 2009;114(15):3147-3157.
3. Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica. 2009;94(8):1044-1048.
4. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357(11):9-19.
5. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357(21):2123-2132. (Pubitemid 350146107)
6. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
7. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA, Italian Multiple Myeloma Network. J Clin Oncol. 2007;25(28):4459-4465.
8. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109(2):492-496.
9. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109(2):465-470. (Pubitemid 46105939)
10. Gertz MA, Comenzo R, Falk RH, et al. Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion From the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319-328. (Pubitemid 41098849)
11. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favourable prognostic factor for survival. J Clin Oncol. 2001; 19(14):3350-3356.
12. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18): 3751-3757.
13. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854-3858. (Pubitemid 43726787)
14. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8): 2936-2938.
15. Palladini G, Foli A, Milani P, et al. Oral melphalan and dexamethasone for Al amyloidosis: efficacy, prognostic factors and response criteria. Amyloid. 2010;17(Suppl1):81-82.
16. Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109(2): 457-464.
17. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351-1358.
18. Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemicAL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8): 1489-1497.
19. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
20. Zonder JA, Sanchorawala V, Snyder RM, et al. Rapid haematologic and organ responses in patients with AL amyloidosis treated with bortezomib plus melphalan and dexamethasone. Amyloid. 2010;17(suppl1):86-87.
21. Dispenzieri A, Gertz MA, Hayman SR, et al. Pomalidomide and dexamethasone for previously treated AL: a phase 2 study. Amyloid. 2010; 17(suppl1):87.
22. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881-1887.
23. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stemcell transplantation. Blood. 2007;110(10): 3561-3563. (Pubitemid 350159622)